In Finance

Follow this topic

Bookmark

Record learning outcomes

Financial expert Vinku Shah explores how dispensing margin really works today, why losses often go unnoticed and how independents can better protect themselves…

For many independent pharmacies, dispensing margin has shifted from being a predictable contributor to profitability to an unstable, retrospective and often misunderstood revenue stream.

While the FP34 dispensing statement remains the NHS’s official record of reimbursement, it does not tell the full story of whether a pharmacy has actually made or lost money on the medicines it dispensed.

Understanding how dispensing margin is created – and eroded – now requires pharmacists to look beyond headline figures, examine how discount assumptions operate in practice and pay closer attention to price fluctuation cost price (PFCP) adjustments.

What the NHS means by dispensing margin

In simple terms, dispensing margin is intended to represent the difference between:

• what the NHS reimburses pharmacies for medicines, and
• what pharmacies are assumed to have paid wholesalers and suppliers.

However, the key word is assumed. The NHS does not assess a pharmacy’s real purchase prices. Instead, it applies nationally set discount deduction rates to different categories of items, regardless of actual buying conditions.

On an FP34 statement, medicines are grouped broadly into generics, branded products, appliances, and discount not deducted (DND) items.

Standard deductions are then applied – historically around 20 per cent for generics, five per cent for branded medicines, and just under 10 per cent for appliances. The underlying assumption is that pharmacies consistently obtain supplier discounts that at least match these rates.

In stable markets, that may hold true. In today’s environment of shortages, price spikes and emergency purchasing, it often does not.

How loss‑making dispensing happens in reality

Consider a common generic liquid antibiotic. The Drug Tariff price may be £1.12. Once the assumed 20 per cent discount is applied, the NHS effectively reimburses around 90p. If supply shortages push the wholesaler price up to £1.40 or more, with no discount available, the pharmacy makes a clear loss on every item dispensed.

These losses rarely appear explicitly on FP34 statements. They are embedded within the overall discount deduction and masked by other items that may still carry some margin. As a result, pharmacies can experience a gradual erosion of profitability without a clear single cause.

The cumulative effect is significant. A loss of 50 pence on a low‑cost item may appear trivial, but repeated dozens or hundreds of times each month, it can quickly remove thousands of pounds from annual operating surplus. This is before taking into accounts costs of dispensing i.e. staff time cost, overheads, etc.

PFCP: The retrospective margin risk

Price fluctuation cost price (PFCP) adjustments introduce an additional and often more damaging layer of risk.

PFCP occurs when the Department of Health and Social Care revises Drug Tariff prices after prescriptions have already been dispensed. Where the revised price is lower, the NHS retrospectively claws back the difference.

On an FP34 statement, PFCP typically appears as a negative adjustment, often attributed disproportionately to generics. Crucially, discount deductions are still applied to these corrected amounts.

This means the pharmacy is not only reimbursed at a lower tariff price, but also loses margin again through the assumed discount mechanism.

From the pharmacy’s perspective, PFCP losses:

• arrive months after dispensing
• cannot be prevented through better buying at the time
• distort month‑to‑month financial comparisons and
• affect cashflow rather than just theoretical margin.

A pharmacy may believe it has traded well in one month, only to discover later that the apparent margin has been retrospectively removed.

Why FP34 alone is not a margin measure

The FP34 statement is a schedule of payments, not a profit and loss report. It shows what the NHS has decided to pay, not whether that payment covers the pharmacy’s real costs.

To understand true dispensing margin, pharmacies must reconcile FP34 figures with supplier invoices. This involves three basic steps:

1.     Identify NHS recognised reimbursement
Use the FP34 total after discount deductions and PFCP adjustments. This represents the gross medicine income recognised by the NHS.

2.     Calculate actual cost of medicines
Aggregate all wholesale and short‑line supplier invoices for the same period (excluding VAT). This should include emergency purchases and one‑off lines.

3.     Compare reimbursement against cost
The difference represents real dispensing margin before overheads such as staffing, rent, utilities and waste.

When this exercise is done consistently, many pharmacies discover that actual margin per item is substantially lower than assumed, often well below 50 pence per prescription.

Protecting margin through better buying discipline

While pharmacists cannot control NHS reimbursement policy, they can exert greater control over how margin risk is managed at purchasing level.

High‑performing pharmacies increasingly adopt a “margin risk” approach rather than pursuing headline discounts.

This involves identifying items that are most likely to generate losses, typically generics subject to shortages, liquids, injectables, and modified‑release formulations, and treating them with additional scrutiny.

Maintaining a simple margin‑risk list can be highly effective. This does not require sophisticated software. A working document identifying high‑risk lines, typical buy prices, and current Drug Tariff values enables teams to spot potential losses before orders are placed.

Where clinically appropriate, pharmacies may also limit quantities supplied of high‑risk items, check multiple suppliers before purchasing, or review whether branded alternatives may provide more predictable reimbursement.

Concession awareness as margin protection

Price concessions remain a critical protection mechanism, but only if they are tracked and claimed correctly. Concessions are drug, strength, form and month‑specific. 

Effective concession management involves checking concession lists frequently, cross‑referencing them with dispensed items, and ensuring endorsements are accurate and legible.

Even a small number of missed concessions each month can wipe out what little margin remains and there is no guarantee that the concessions will roll over into the following month. Cumulatively these will have a large adverse impact.

Spotting PFCP‑driven erosion early

Although PFCP cannot be prevented, its impact can be anticipated. Warning signs include unexplained drops in reimbursement despite stable script volume, large negative generic PFCP lines on FP34, and noticeable tariff price reductions on commonly dispensed medicines.

Pharmacies that monitor Drug Tariff changes and track the items most exposed to repricing are better placed to understand cashflow fluctuations and avoid misinterpreting PFCP losses as operational failure.

Margin must be managed, not assumed

Dispensing margin in community pharmacy is no longer a passive outcome of volume and discount structures. It is fragile, retrospective, and increasingly disconnected from day‑to‑day dispensing activity.

FP34 statements remain essential, but they are only a starting point. Without linking reimbursement data to real purchasing costs, pharmacies risk overestimating performance and underestimating financial vulnerability.

In the current climate, the most resilient pharmacies are those that treat margin as something to be actively monitored, challenged and protected, item by item, month by month, rather than assumed to exist simply because dispensing continues.

Vinku Shah is a partner at Xeinadin.